NGF、Noggin基因修饰的rBMSCs移植治疗帕金森病大鼠模型的实验研究
|
摘要
研究目的：1.通过立体定向技术将6-OHDA直接注射到前脑内侧束来建立一种简单、有效的PD大鼠模型,为下一步研究奠定基础。2.建立大鼠骨髓间充质干细胞体外分离、扩增方法。3.判断重组腺病毒Ad-GFP、Ad-GFP-NGF、Ad-GFP-NOGGIN对rBMSCs的转染效率、转染对细胞的影响以及目的蛋白的表达情况。4.对比观察化学诱导剂、NGF及Noggin对rBMSCs像神经元样细胞方向分化的诱导作用。5.探讨携带NGF及Noggin的rBMSCs对PD模型大鼠神经功能的修复作用及其机制。
研究方法：1.应用6-OHDA立体定向颅内注射制备PD大鼠模型。用阿朴吗啡皮下注射检测造模是否成功。2.取SD大鼠长骨骨髓作为供体来源,经贴壁筛选法进行体外培养并纯化rBMSCs。通过细胞表面标志、成骨细胞诱导和成脂细胞诱导对培养的细胞进行鉴定。3.通过不同浓度的重组腺病毒选择转染最合适的MOI值。将rBMSCs分成5组分别为未转染组、Ad-GFP转染组、Ad-GFP-NGF转染组、Ad-GFP-Noggin转染组和Ad-GFP-NGF、Ad-GFP-Noggin联合转染组,观察转染对rBMSCs生长的影响,通过免疫荧光检测目的蛋白的表达。4.通过化学诱导剂和基因修饰诱导rBMSCs向神经元样细胞方向分化,并检测其神经细胞标志物的表达。5.通过立体定向颅内注射将经过基因修饰的rBMSCs移植入模型大鼠损毁侧纹状体。记录单位时间阿朴吗啡诱发的模型大鼠旋转次数,观察大鼠神经功能恢复情况。通过免疫荧光检测移植细胞在脑内存活、分布以及向神经元、星形胶质细胞方向分化的情况。免疫组化法检测细胞移植后第四周大鼠中脑黑质TH阳性细胞计数。通过高效液相检测大鼠纹状体DA、DOPAC、HVA含量。
结果：1.6-OHDA颅内注射制备的帕金森病大鼠模型具有良好的稳定性,该模型的制备为下一步实验奠定了基础。2.贴壁法能够筛选获得纯度较高,活性良好的rBMSCs,具有相关表型,能向成骨细胞和成脂细胞分化。3.重组腺病毒Ad-GFP、Ad-GFP-NGF、Ad-GFP-Noggin在MOI=50pfu/cell条件下对rBMSCs转染效率高,对rBMSCs毒性最小。经NGF、Noggin修饰的重组腺病毒转染后的rBMSCs在发出绿色荧光的同时,能分别表达相应蛋白产物,免疫荧光染色呈红色荧光。联合转染组rBMSCs则同时呈现NGF、Noggin免疫荧光阳性反应。4.rBMSCs在化学诱导剂作用下,5h后出现神经元样形态,免疫荧光染色显示神经元标志物NF(H)呈阳性,星形胶质细胞标志物GFAP呈阴性,但细胞大量死亡。各转染组rBMSCs中Ad-GFP转染组细胞形态无改变,Ad-GFP-NGF转染组、Ad-GFP-Noggin转染组及联合转染组rBMSCs在转染后72h呈现神经元样形态,部分细胞免疫荧光染色显示NF(H)阳性,GFAP阴性,分化后的细胞可长期存活。其中联合转染组NF(H)阳性率最高。5.经立体定向将细胞移植入模型大鼠损毁侧纹状体一周后,大鼠神经功能均有所改善,由阿朴吗啡诱发的旋转次数明显减少,其中联合转染组最为明显。镜下发现,移植细胞自注射部位向周围扩散,分布于纹状体、皮层下、海马及对侧半球。移植后两周,免疫荧光检测部分存活移植细胞NF(H)有阳性表达,另有部分细胞呈GFAP阳性。联合转染组NF(H)和GFAP阳性细胞比例最高。移植后四周,免疫组化检测各组模型黑质TH阳性细胞生存率,基因修饰组有增多的趋势,但各组差异无统计学意义。高效液相检测大鼠纹状体DA、DOPAC、HVA含量损毁侧同健侧之比,各细胞移植组比值均较未移植组和PBS组高,其中Ad-GFP-NGF和Ad-GFP-Noggin联合转染组比值最高。
结论：1.6-OHDA立体定向颅内注射法制备PD大鼠模型具有良好的稳定性及可重复性。2.通过贴壁筛选法能有效纯化骨髓,获得高纯度rBMSCs,并且该方法简单实用,对细胞影响小,能满足大多数研究需求。通过流式细胞技术检测细胞表面标志,以及成骨、成脂诱导能够对rBMSCs进行有效鉴定。3.重组腺病毒Ad-GFP、Ad-GFP-NGF和Ad-GFP-Noggin均能安全、有效地转染体外培养的大鼠BMSCs,并稳定表达GFP、NGF和Noggin蛋白。4.体外环境下,化学诱导剂和NGF和Noggin蛋白均能将rBMSCs诱导成为神经元样细胞,但化学诱导剂对细胞存活有明显影响,而后两者不影响细胞存活,并可促进细胞向神经元方向分化。5.立体定向将基因修饰的rBMSCs移植入大鼠损毁侧纹状体,移植细胞可在脑内存活、迁移并分化为具有神经元或星形胶质细胞表型的细胞,通过多种途径有效改善模型大鼠神经功能,促进DA的释放。
Objective:1. Establish a simple and effective rat model of Parkinson'disease by direct injection of 6-hydroxydopamine(6-OHDA) in the middle forebrain bundle(MFB) with stereotactic technique, and offer an experimental basement for the next research.2. Establish a method to isolate and culture the rat bone mesenchymal stem cells(rBMSCs).3. Study the transfect efficiency of three kinds of recombinant adenovirus including Ad-GFP, Ad-GFP-NGF and Ad-GFP-Noggin. The influence of transfection and the expression of NGF and Noggin were observed.4. The effects of chemical supplement, NGF and/or Noggin in inducing rBMSCs into neuron-like cells were discussed.5. To explore the effects and mechanisms on recovery of neurological function observed in rats of PD model grafted by rBMSCs modified with NGF and/or Noggin.
Methods:1. Establish a rat model of PD by direct injection of 6-OHDA in MFB. To check if the establishment of PD rat model was successive by hypodermical injection of apomorphine.2. rBMSCs were isolated from rat bone marrow and purified through adherence ability. The cells were identified as rBMSCs by their phenotypical properties and their ability of differentiating into osteocyte and adipocyte.3. The proper MOI was chosen through recombinant adenovirus different density. rBMSCs were divided into 5 groups:rBMSCs, rBMSCs transfected with Ad-GFP, rBMSCs transfected with Ad-GFP-NGF, rBMSCs tarnsfected with Ad-GFP-Noggin and rBMSCs transfected with Ad-GFP-NGF combined with Ad-GFP-Noggin. Detect the influence of transfection to rBMSCs and the expression of NGF and Noggin through immunofluorescence.4. Induce rBMSCs differentiate into neuron-like cell and observe their expression of neuron specific marking proteins NF(H).5. rBMSCs modified by different genes were injected into the lesion side of striatum of PD model rats by stereotactic apparatus. Rotation test evoked by apomorphine was used to study the recovery of neurological deficits of rats. The distribution of survival transplanted cells was observed, and their diffentiation into neurons and astrocytes was detected through immunofluorescence. Four weeks after implantation, the number of TH positive cells in nigra was detected through immunohistochemical assessment. The contents of DA(dopamine)、DOPAC(dihydroxyphenylacetic) and HVA(homovanillic acid) in striatum of model rats were detected by high performance liquid chromatography-electric-chemical discharge(HPLC-ECD).
Results:1. The PD model established by injecting 6-OHDA into rat's MFB is a stable PD model. The establishment of the model had offered a basement for further experiment.2. The cells pure by their adherence ability had basic phenotypical properties of rBMSCs, and could differentiate into osteocyte and adipocyte.3. When MOI=50, Ad-GFP Ad-GFP-NGF and Ad-GFP-Noggin could transfect rBMSCs with high efficiency and low toxicity. rBMSCs transfected with recombinant adenovirus had green fluorescence autonomically at the same time it could express corresponding protein and send out red fluorescence through immunofluorescence. rBMSCs transfected with both Ad-GFP-NGF and Ad-GFP-Noggin had positive reaction to both NGF or Noggin at the same time.4. Neuron-like appearance could be seen after rBMSCs had been cultured in chemical supplement for 5h. NF(H),but astrocytic marking protein GFAP, was positive in them. Most of cells died in this supplement. The shape of rBMSCs transfected with Ad-GFP was not change. In the three groups transfected with Ad-NGF、Ad-Noggin and the two virus, the cells got the shape of neuron 72h later, some of them were positive to NF(H) and negative to GFAP. These cells grew in good state. The ratio of NF(H)+cells in combinating transfected group was the highest.5. One week after injection of the modified rBMSCs into lesion side striatum of rat model, the neurological function of rats was improved, the apomorphine-induced rotation was reduced significantly, the decrement of the combined group was remarkable. Observed by microscope, survival rBMSCs could be seen in striatum, subcortex, hippocampus which around the injective position and even the opposite side hemisphere. Two weeks after implantation, some of the survival cells were positive to NF(H) and some others were positive to GFAP. The rats transplanted with rBMSCs modified with two genes had more survival cells and higher ratio of NF(H)+ or GFAP+ cells than other groups. Four weeks after implantation, the survival rate of TH positive cells in nigra was found an increased tendency in the combined group. But the difference of each group was not statistically significant. The contents of DA, DOPAC and HVA in lesion side and uninjured side were detected by HPLC, their ratio of each group was compared. The ratio of groups that implanted with rBMSCs was higher than the group with PBS and group with no implantation. The ratio of group that implanted with rBMSCs which modified with two genes was the highest in all groups.
Conclusion:1. The PD rat model established by intracal injection of 6-OHDA has good stability and repeatability.2. rBMSCs could be isolated and purified from rat bone marrow through their adherence ability and subculture. This method was simple, and would not influence the activity of cells. rBMSCs could be identified effectively by phenotypical properties and multipotency.3. Ad-GFP, Ad-GFP-NGF and Ad-GFP-Noggin could transfect rBMSCs safely. The transfected cells could express GFP, NGF and Noggin effectively.4. Chemical supplement, NGF and Noggin could induce rBMSCs into neuron-like cells in vitro. But chemical supplement interrupted the survival of cells, while NGF and Noggin could improve their differentiation.5. rBMSCs modified with NGF and Noggin could be implanted into the lesion side striatum of rat model. The transplanted rBMSCs could survive and migrate in the brain of model rats. Some of them could differentiate into cells with phenotype of neuron or astrocyte. The transplanted rBMSCs could improve the recovery of neurological function and the delivery of DA in rat model by several effective ways.
研究方法：1.应用6-OHDA立体定向颅内注射制备PD大鼠模型。用阿朴吗啡皮下注射检测造模是否成功。2.取SD大鼠长骨骨髓作为供体来源,经贴壁筛选法进行体外培养并纯化rBMSCs。通过细胞表面标志、成骨细胞诱导和成脂细胞诱导对培养的细胞进行鉴定。3.通过不同浓度的重组腺病毒选择转染最合适的MOI值。将rBMSCs分成5组分别为未转染组、Ad-GFP转染组、Ad-GFP-NGF转染组、Ad-GFP-Noggin转染组和Ad-GFP-NGF、Ad-GFP-Noggin联合转染组,观察转染对rBMSCs生长的影响,通过免疫荧光检测目的蛋白的表达。4.通过化学诱导剂和基因修饰诱导rBMSCs向神经元样细胞方向分化,并检测其神经细胞标志物的表达。5.通过立体定向颅内注射将经过基因修饰的rBMSCs移植入模型大鼠损毁侧纹状体。记录单位时间阿朴吗啡诱发的模型大鼠旋转次数,观察大鼠神经功能恢复情况。通过免疫荧光检测移植细胞在脑内存活、分布以及向神经元、星形胶质细胞方向分化的情况。免疫组化法检测细胞移植后第四周大鼠中脑黑质TH阳性细胞计数。通过高效液相检测大鼠纹状体DA、DOPAC、HVA含量。
结果：1.6-OHDA颅内注射制备的帕金森病大鼠模型具有良好的稳定性,该模型的制备为下一步实验奠定了基础。2.贴壁法能够筛选获得纯度较高,活性良好的rBMSCs,具有相关表型,能向成骨细胞和成脂细胞分化。3.重组腺病毒Ad-GFP、Ad-GFP-NGF、Ad-GFP-Noggin在MOI=50pfu/cell条件下对rBMSCs转染效率高,对rBMSCs毒性最小。经NGF、Noggin修饰的重组腺病毒转染后的rBMSCs在发出绿色荧光的同时,能分别表达相应蛋白产物,免疫荧光染色呈红色荧光。联合转染组rBMSCs则同时呈现NGF、Noggin免疫荧光阳性反应。4.rBMSCs在化学诱导剂作用下,5h后出现神经元样形态,免疫荧光染色显示神经元标志物NF(H)呈阳性,星形胶质细胞标志物GFAP呈阴性,但细胞大量死亡。各转染组rBMSCs中Ad-GFP转染组细胞形态无改变,Ad-GFP-NGF转染组、Ad-GFP-Noggin转染组及联合转染组rBMSCs在转染后72h呈现神经元样形态,部分细胞免疫荧光染色显示NF(H)阳性,GFAP阴性,分化后的细胞可长期存活。其中联合转染组NF(H)阳性率最高。5.经立体定向将细胞移植入模型大鼠损毁侧纹状体一周后,大鼠神经功能均有所改善,由阿朴吗啡诱发的旋转次数明显减少,其中联合转染组最为明显。镜下发现,移植细胞自注射部位向周围扩散,分布于纹状体、皮层下、海马及对侧半球。移植后两周,免疫荧光检测部分存活移植细胞NF(H)有阳性表达,另有部分细胞呈GFAP阳性。联合转染组NF(H)和GFAP阳性细胞比例最高。移植后四周,免疫组化检测各组模型黑质TH阳性细胞生存率,基因修饰组有增多的趋势,但各组差异无统计学意义。高效液相检测大鼠纹状体DA、DOPAC、HVA含量损毁侧同健侧之比,各细胞移植组比值均较未移植组和PBS组高,其中Ad-GFP-NGF和Ad-GFP-Noggin联合转染组比值最高。
结论：1.6-OHDA立体定向颅内注射法制备PD大鼠模型具有良好的稳定性及可重复性。2.通过贴壁筛选法能有效纯化骨髓,获得高纯度rBMSCs,并且该方法简单实用,对细胞影响小,能满足大多数研究需求。通过流式细胞技术检测细胞表面标志,以及成骨、成脂诱导能够对rBMSCs进行有效鉴定。3.重组腺病毒Ad-GFP、Ad-GFP-NGF和Ad-GFP-Noggin均能安全、有效地转染体外培养的大鼠BMSCs,并稳定表达GFP、NGF和Noggin蛋白。4.体外环境下,化学诱导剂和NGF和Noggin蛋白均能将rBMSCs诱导成为神经元样细胞,但化学诱导剂对细胞存活有明显影响,而后两者不影响细胞存活,并可促进细胞向神经元方向分化。5.立体定向将基因修饰的rBMSCs移植入大鼠损毁侧纹状体,移植细胞可在脑内存活、迁移并分化为具有神经元或星形胶质细胞表型的细胞,通过多种途径有效改善模型大鼠神经功能,促进DA的释放。
Objective:1. Establish a simple and effective rat model of Parkinson'disease by direct injection of 6-hydroxydopamine(6-OHDA) in the middle forebrain bundle(MFB) with stereotactic technique, and offer an experimental basement for the next research.2. Establish a method to isolate and culture the rat bone mesenchymal stem cells(rBMSCs).3. Study the transfect efficiency of three kinds of recombinant adenovirus including Ad-GFP, Ad-GFP-NGF and Ad-GFP-Noggin. The influence of transfection and the expression of NGF and Noggin were observed.4. The effects of chemical supplement, NGF and/or Noggin in inducing rBMSCs into neuron-like cells were discussed.5. To explore the effects and mechanisms on recovery of neurological function observed in rats of PD model grafted by rBMSCs modified with NGF and/or Noggin.
Methods:1. Establish a rat model of PD by direct injection of 6-OHDA in MFB. To check if the establishment of PD rat model was successive by hypodermical injection of apomorphine.2. rBMSCs were isolated from rat bone marrow and purified through adherence ability. The cells were identified as rBMSCs by their phenotypical properties and their ability of differentiating into osteocyte and adipocyte.3. The proper MOI was chosen through recombinant adenovirus different density. rBMSCs were divided into 5 groups:rBMSCs, rBMSCs transfected with Ad-GFP, rBMSCs transfected with Ad-GFP-NGF, rBMSCs tarnsfected with Ad-GFP-Noggin and rBMSCs transfected with Ad-GFP-NGF combined with Ad-GFP-Noggin. Detect the influence of transfection to rBMSCs and the expression of NGF and Noggin through immunofluorescence.4. Induce rBMSCs differentiate into neuron-like cell and observe their expression of neuron specific marking proteins NF(H).5. rBMSCs modified by different genes were injected into the lesion side of striatum of PD model rats by stereotactic apparatus. Rotation test evoked by apomorphine was used to study the recovery of neurological deficits of rats. The distribution of survival transplanted cells was observed, and their diffentiation into neurons and astrocytes was detected through immunofluorescence. Four weeks after implantation, the number of TH positive cells in nigra was detected through immunohistochemical assessment. The contents of DA(dopamine)、DOPAC(dihydroxyphenylacetic) and HVA(homovanillic acid) in striatum of model rats were detected by high performance liquid chromatography-electric-chemical discharge(HPLC-ECD).
Results:1. The PD model established by injecting 6-OHDA into rat's MFB is a stable PD model. The establishment of the model had offered a basement for further experiment.2. The cells pure by their adherence ability had basic phenotypical properties of rBMSCs, and could differentiate into osteocyte and adipocyte.3. When MOI=50, Ad-GFP Ad-GFP-NGF and Ad-GFP-Noggin could transfect rBMSCs with high efficiency and low toxicity. rBMSCs transfected with recombinant adenovirus had green fluorescence autonomically at the same time it could express corresponding protein and send out red fluorescence through immunofluorescence. rBMSCs transfected with both Ad-GFP-NGF and Ad-GFP-Noggin had positive reaction to both NGF or Noggin at the same time.4. Neuron-like appearance could be seen after rBMSCs had been cultured in chemical supplement for 5h. NF(H),but astrocytic marking protein GFAP, was positive in them. Most of cells died in this supplement. The shape of rBMSCs transfected with Ad-GFP was not change. In the three groups transfected with Ad-NGF、Ad-Noggin and the two virus, the cells got the shape of neuron 72h later, some of them were positive to NF(H) and negative to GFAP. These cells grew in good state. The ratio of NF(H)+cells in combinating transfected group was the highest.5. One week after injection of the modified rBMSCs into lesion side striatum of rat model, the neurological function of rats was improved, the apomorphine-induced rotation was reduced significantly, the decrement of the combined group was remarkable. Observed by microscope, survival rBMSCs could be seen in striatum, subcortex, hippocampus which around the injective position and even the opposite side hemisphere. Two weeks after implantation, some of the survival cells were positive to NF(H) and some others were positive to GFAP. The rats transplanted with rBMSCs modified with two genes had more survival cells and higher ratio of NF(H)+ or GFAP+ cells than other groups. Four weeks after implantation, the survival rate of TH positive cells in nigra was found an increased tendency in the combined group. But the difference of each group was not statistically significant. The contents of DA, DOPAC and HVA in lesion side and uninjured side were detected by HPLC, their ratio of each group was compared. The ratio of groups that implanted with rBMSCs was higher than the group with PBS and group with no implantation. The ratio of group that implanted with rBMSCs which modified with two genes was the highest in all groups.
Conclusion:1. The PD rat model established by intracal injection of 6-OHDA has good stability and repeatability.2. rBMSCs could be isolated and purified from rat bone marrow through their adherence ability and subculture. This method was simple, and would not influence the activity of cells. rBMSCs could be identified effectively by phenotypical properties and multipotency.3. Ad-GFP, Ad-GFP-NGF and Ad-GFP-Noggin could transfect rBMSCs safely. The transfected cells could express GFP, NGF and Noggin effectively.4. Chemical supplement, NGF and Noggin could induce rBMSCs into neuron-like cells in vitro. But chemical supplement interrupted the survival of cells, while NGF and Noggin could improve their differentiation.5. rBMSCs modified with NGF and Noggin could be implanted into the lesion side striatum of rat model. The transplanted rBMSCs could survive and migrate in the brain of model rats. Some of them could differentiate into cells with phenotype of neuron or astrocyte. The transplanted rBMSCs could improve the recovery of neurological function and the delivery of DA in rat model by several effective ways.
引文
1. Glinka Y, GassenM, Youdim MB. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl,1997,50:55-66.
2. Ahn TB,Kim Jm,Kwon KM,et al. Survival and migration of transplanted neural stem cell-derived dopamine cells in the brain of parkinsonian rat. Int J Neurosci,2004,114(5):575-585.
3. Yasuhara T, Shingo T, Muraoka K,et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg, 2005,102(1):80-89.
4. Schober A. Classic toxin-induced animal models of Parkinson's disease:6-OHDA and MPTP. Cell Tissue Res,2004,318 (1):215-224.
5. Langston JW, Forno LS, Testrud J, et al. Evidence of active cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyk-1,2,3,6-tetrahydropyridine exposure. Ann Neurol,1999,46:598-605.
6. Javitch JA,D'Amato RJ,Strittmatter SM,et al. Parkinsonism inducing neurotoxin,N-methyl-4-henyl-1,2,3,6-tetrahydropyridine:uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA,1985,82:2173-2177.
7. Tipton KF, Singer TP. Advances in our understanding of the mechanism of the neurotoxicity of MPTP and related compounds. J Neurochem, 1993,61:1191-1206.
8. Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinemodel of Parkinson's disease. Proc Natl Acad Sci USA,2003,100(10):6145-50.
9. Sriram K, Pai KS, Boyd MR, et al. Evidence for generation of oxidative stress in brain by MPTP:in vitro and in vivo studies in mice. Brain Res,1997,749:44-52.
10. Hantraye P, Varastet M, Peschanski M, et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience,1993,53:169-178.
11. Brooks AI, Chadwick CA, Gelbard HA, et al. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.Brain Res,1999,823:1-10.
12. Shimizu K, Matsubara K, Ohtaki K, et al. Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture. Neurosci Res,2003,46(4):523-532.
13. Takahashi RN, Rogerio R, Zanin M. Maneb enhances MPTP neurotoxicity in mice. Res Commun Chem Pathol Pharmacol,1989,66:167-170.
14. Thiruchelvam M, Richfield EK, Baggs RB, et al. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb:implications for Parkinson's disease. J Neurosci,2000,20:9207-9214.
15. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci,2000,3:1301-1306.
16. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase:an overview. Biochim Biophys Acta,1998,1364(2):222-235.
17. Ben-shachar D, Youdim MB. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem,1991,57(6):2133-2135.
18. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alphasynuclein mice:implications for neurodegenerative disorders. Science,2000,287(5456):1265-1269.
19. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature,2000,404(6776):394-398.
20. Barneroud P, Parmentier S, Mazadier M, et al. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat.Neuroscience,1995,67(4):837-848.
21. Przedvorski S, Levieier M, et al. Dose dependent lesion of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-OHDA. Neuroscience,1995,67:631-647.
22. Olsson M,Nikkhah G,Bentlage C,et al. Forelimb akinesia in the rat Parkinson model:differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.J Neurosci,1995,15(5):3863～3875.
23. Ellenbroek BA, Peeters BW, Honig WM,et al. The paw test:a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology(Berl),1987,93(3):343～348.
24. Montoya CP, Campbell-Hope LJ, Pemberton KD, et al. The"staircase test":a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods,1991,36(2-3):219～228.
25. Cousins MS, Salamone JD. Involvement of ventrolateral striatal dopamine in movement initiation and execution:a microdialysis and behavioral investigation. Neuro science,1996,70(4):849～859.
26. Amalric M, Moukhles H, Nieoullon A, et al. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci,1995,7(5):972～980.
27. Whishaw IQ, Dunnett SB. Dopamine depletion, stimulation or blockade in the rat disrupts spatial navigation and locomotion dependent upon beacon or distal cues. Behav Brain Res,1985,18(1):11～29.
28. Carman LS, Gage FH, Shults CW,. Partial leision of the substantia nigra:relation between extent of lesion and rotational behavior. Brain Res, 1991,553(2);275-283.
29. Perese DA, Ulman J, Viola J, et al. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res,1989,494(2):285-293.
30. Barneoud P, Parmentier S, Mazadier M, et al. Effect s of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat.Neuroscience,1995,67(4):837～848.
31. Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesion of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol,1996,49(3):215-266.
32. Signore AP, Weng Z, Hastings T, et al. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem, 2006,96(2):428-443
33. Evans MJ, Kauman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature.1981;292(9):154.
34. Friedenstein AJ. Precursor cells of mechynocytes. Int Rev Cytol,1968, 47:327-355
35. Pittenger MF, Machay AM, Bech SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science,1999,284(5411):143-147
36. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med,2001, 226(6):507-520
37. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature,2002,418(6893):41-49
38. Cai YF, Zhen ZJ, Min J. Selection, proliferation and differentiation of bone marrow-derived liver stem cells with a culture system containing cholestatic serum in vitro. World J Gastroenterol,2004,10(22):3308-3312
39. Fraser JK, Zhu M, Wulur I. Adipose-derived stem cells. Methods Mol Biol.2008, 449:59-67.
40. Kim SJ, Lee JK, Kim JW, et al. Surface modification of polydimethylsiloxane (PDMS) induced proliferation and neural-like cells differentiation of umbilical cord blood-derived mesenchymal stem cells.J Mater Sci Mater Med.2008,24
41. Caplan AI. Mesenchymal stem cells. J Orthop Res.1991,9(5):641-650
42. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells:invitro cultivation transplantation in diffusion chambers. Cell Tissue, 1987,20:263
43. Pittenger M F, Mackay A M, Jaisdwal S C, et al. Multilineage potential of adult human mesemchymal stem cells[J]. Science,1999,284(5411):143-147
44. Zhang Y, Lin HK, Frimberger D, et al. Growth of bone marrow stromal cells on small intestinal submucosa:an alternative sell source for tissue engineered bladder. BJU Int,2005,96(7):1120-1125
45. Sasaki DT, Tichenor EH, Lopez F, et al. Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. J Hematother.1995 Dec;4(6):503-14.
46. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol,2000,164(2):247-256
47. Deryugina EI, Muller-sieburg CE. Stromal cells in longterm cultures:keys to the elucidation of hematopoietic development. Crit Rev Immunol,1993,13:115-121
48. Kitano Y, Radu A, Shabban A, et al. Selection, enrichment, and culture expansion of murine mesenchymal progenitor cells by retroviral transduction of cycling adherent bone marrow cells. Exp Hemato,2000,28(12):1460-1469
49. David C C, Reiner C, Carla M et al. Rapid expansion of recycling stem cells in cultrues of plastic2adherent cells from human bone marrow. Proc Natl Acad Sci USA,2000,97(7):3213-3218.
50. Bruder S P, Jaiswal N, Haynesworth S E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subculativation and following cryopreservation. J Cell Biochem,1997,64:278-294.
51. Lennon D P, Haynesworth S E, Young R G, et al. A chemically defined medium supprots in vitro proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells. Exp Cell Res,1995,219(1):211-222.
52. Jachson L, Jones DR, Scotting P, et al. Adult mesenchymal stem cells: Differentiation potential and therapeutic applications. J Postgrad Med,2007, 53(2):121-127
53. Gregory CD, Devitt A, etal. CD14 and apoptosis. Apoptosis 1999,4:11-20
54. Kranse DS, Fackler MJ, Civin Cl, et al. CD34:Structure, biology, and clinical utility. Blood,1996; 87:1-13
55. Haynes BF et al. Cancer Cells,1991;3(9):347-350//Korfuruta et al.Clin Cancer Res,1998,4:21-29
56. Hou M, et al. Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats. Int J Cardiol.2007,115(2): 220-8
57. M Dominicil,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy.2006,8(4):315-317
58. Mai Hou, et al. Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats. International Journal of Cardiology.2007,115 () 220-228
59. Heterogeneity of stromal precursor cells isolated from rat bone marrow. Tsitologiia.2007,49(1):40-47
60. Yamaguchi T, Chattopadhyay N, Kifor O, et al. Extracellular calcium (Ca2+(O))-sensing receptor in a murine bone marrow-derived stromal cell line (ST2):potential mediator of the actions of Ca2+(O) on the function of ST2 cells. Endocrinology,1998,139:3561-38568
61. Tang QQ, Jiang MS, Lane MD. Repressive effect of Spl on the C/EBPalpha gene promoter:role in adipocyte differentiation. Mol Cell Biol,1999,19:4855-4865
62. Klemm DJ, Roesler WJ, Boras T, et al. Insulin stimulates c AMP-response element binding protein activity in JepG2 and 3T3-L1 cell lines. J Biol Chem, 1998,273:917-923
63. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferators-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs, J Biol Chem,1997,272:3406-3410
64. Varga F, Luegmayr E, Fratzl-Zelman N, et al. Tri-iodothyronine inhibits multilayer formation of the osteoblastic cell line, MC3T3-E1, by promoting apoptosis. J Endocrinol,1999,160:57-65
65. Coelho MJ, Fernandes MH. Human bone cell cultures in biocompatibility testing. Part Ⅱ:effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation. Biomaterials,2000,21:1095-1102
66. Otsuka E, Yamaguchi A, Hirose S, et al. Characterization of osteoblastic differentiation of stromal cell line ST2 that is induced by ascorbic acid. Am J Physiol,1999,277:C132-138
67. Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear location signals for nonviral gene transfer. Gen Ther,2002,9:157-167
68. Mh C, Byrne BJ, Flotte TR. Virus-base gene delivery system. Clin Pharmacokinet, 2002,41:901-911
69. Kurai T, Shimada T. Recombinant adeno-associated virus-mediated gene delivery to the central nervous system. J Nippon Med Sch,2007; 74(3):188-189.
70. Kozlowski M, Olson DE, Rubi n J,et al. Adenoassociated viral delivery of a metabolically regulated insulin transgene to hepatocytes. Mol Cell Endocrino,2007; 273(1-2);6-15.
71. Rabie AB, Dai J, Xu R. Recombinant AAV- mediated VEGF gene therapy induces mandibular condylar growth. Gene Ther,2007; 14(12):972-980.
72. Yeh P, Perricaudet M. Advances in adenoviral vectors:From genetic engineering to their biology. FASEB J,1997,11:615-623
73. Balci b, Yilmaz O. Extent of coronary collateral vessel decrease with advanced age. Acta Cardiol.2004,59(4):431-434
74. Rissanen TT, Rutanen J, Yla-Herttuala S. Gene transfer for therapeutic vascular growth in growth in myocardial and peripheral ischemia. Adv Genet.2004,52: 117-164
75. Monaham PE, Samulski RJ. Adeno-associated virus vectors for gene therapy, more pros than cons? Mol Med Today,2000,6:433-440
76. LS Young, V Mautner. The promise and potential hazards of adenovirus gene therapy. Gut,2001,48:733-736
77. Menei P, Montero-Menei C, Whittenore SR, et al. Schwann cells genetically modified to secrete human BDNF promote enhanced axonal regrowth across transected adult rat spinal cord. Eur J Neurosci,1998,10:607-621
78. Le BK, Tammik C, Rosendahl K, et al. HLA expression and immunologic proterties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol,2003,31:890-896
79. Le BK, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol,2003,57:11-20
80. Chen ZM, O'Shaughnessy MJ, Gramaglia I, et al. IL-10 and TGF-beta induce alloreactive CD4+ CD25- T cells to acquire regulatory cell function. Blood,2003, 101:5076-5083
81. Valero A, Post JN, van Nieuwkasteele JW, et al. Gene transfer and protein dynamics in stem cells using single cell electroporation in a microfluidic device. Lab Chip,2008,8(1):62-7
82. Meinel L, Hofmann S, Betz O,et al. Osteogenesis by human mesenchymal stem cells cultured on silk biomaterials:comparison of adenovirus mediated gene transfer and protein delivery of BMP-2. Biomaterials.2006,27(28):4993-5002
83. Kyriakou CA, Yong KL, Benjamin R,et al. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med.2006,8(3):253-64
84. Shih CH, Cheng YL, Song KS. Lineage differentiation-associated loss of adenoviral susceptibility and coxsachie-adenovirus receptor expression in human mesenchymal stem cell. Stem cells,2004,22:1321-1329
85. Tsien RY. The green fluorescent protein. Annu Rev Biochem,1998,67:509-544
86. Chalfie M, Tu Y, Euskirhen G, et al. Green fluorescent protein as a marker for gene expression. Science,1994,263:802-805
87. Hong SS, Karayan L, Tournier J, et al. Adenovirus type 5 fiber knob binds to MHC class I a 2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J,1997,16:2291-2306
88. Walters RW, Grunst T, Bergelson JM, et al. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem,1999,274:10219-10226
89. Ss-eisler A, Falck-pedersen E, Alvira M, et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA,1993,90:11498-11502
90. Frey M, Hachett NR, Bergelson JM, et al. High-efficiency gene transfer into exvivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors. Blood,1998,91:2781-2792
91.Halleux C, Sottile V, Gasser J A, et al. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskel Neuron Interact,2001,2(1):71-76.
92. Tropel P, Platet N, Platel JC, et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells.Stem Cells.2006,24(12):2868-76
93. Wislet-Gendebien S, Wautier F, Leprince P, et al. Astrocytic and neuronal fate of mesenchymal stem cells expressing nestin. Brain Res Bull.2005,68(1-2):95-102
94. Wislet-Gendebien S, Hans G, Leprince P, et al. Plasticity of cultured mesenchymal stem cells:switch from nestin-positive to excitable neuron-like phenotype.Stem Cells.2005,23(3):392-402
95. Song S, Song S, Zhang H, et al. Comparison of neuron-like cells derived from bone marrow stem cells to those differentiated from adult brain neural stem cells. Stem Cells Dev.2007,16(5):747-56
96. Kohyama et al. Brain from bone:Efficent'meta-differentiation'of marrow stromal-derived cell mature osteoblasts to neurons with Noggin or demythylating agent. Differentiation,2001(68):235-244
97. Woodbury D, Schwarz EJ, Prochop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res,2000,61(4):364-370
98. Suzuki H, Taguchi T, Tanaka H, et al. Neurospheres induced from bone marrow stromal cells are multipotent for differentiation into neuron, astrocyte, and oligodendrocyte phenotypes. Bioche Biophys Res Commun,2004,322:918-922.
99. Jori FP, Napolitano MA, Melone MA, et al. Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J CellBiochem,2005, 94:645-655
100. Lei Z, Yongda L, Jun M, Yingyu S, et al. Culture and neural differentiation of rat bone marrow mesenchymal stem cells in vitro.Cell Biol Int.2007,31(9): 916-23
101. Tao H, Rao R, Ma DD.Cytokine-induced stable neuronal differentiation of human bone marrow mesenchymal stem cells in a serum/feeder cell-free condition.Dev Growth Differ.2005,47(6):423-33
102. Kim S, Honmou O, Kato K, et al. Neural differentiation potential of peripheral blood and bone marrow derived precursor cells. Brain Res. 2006, 1123(1):27-33
103. Long X, Olszewski M, Huang W. Neural cell differentiation in vitro from adult human bone marrow mesenchymal stem cells. Stem Cells Dev.2005,14(1): 65-9
104. Hoener-MC, Hewirr E, Connner M, et al. Nerve growth factor (NGF) content in adult rat brain tissues is several-fold higher than generally reported and id largely associated with sedimentable fractions. Brain Res,1996,728(1):47-56
105. Levi MR. The nerve growth factor 35 years later. Science,1987,237: 1154-1158
106. Covaceuszach S, Cattaneo A, Lamba D. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody M AC 13:a structural insight. Proteins,2005,58(3):717-72
107. Bilderback TR, Gazula VR, Dobrowsky RT. Phosphoinositide 3-kinase regulates crosstalk between Trk A tyrosine kinase and p75 (NTR)-dependent sphingolipid signaling pathways. J Neurochem,2001,76(5):1540-1551
108. Ibanez CF. Structure-function relationships in the neurotrophin family. J Neurobiol,1994,25:1349-1361
109. Yuen EC, Mobley WC. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol,1996,40:346-354
110. Yoon SO, Casaccia BP, Carter B, et al. Competitive signaling between TrkA and P75 nerve growth factor receptors determines cell survival. J Neurosci,1998, 18:3273-3279
111. Baker SJ, Reddy EP. Transducers of life and death:TNF receptor superfamily and associated proteins. Oncogene,1996,12:1-9
112. Frade JM, Rodriguez TA, Barde YA. Induction of cell death by endogenous NGF through its P75 receptor. Nature,1996,383:166-172
113. Anton ES. Nerve growth factor and its low-affinity receptor promote Schwann cell migration. Proc Natl Acad Sci USA,1994,91:2795-2799
114. Choong PF, Mok PL, Cheong SK, et al. Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy.2007,9(2):170-83
115. Tondreau T, Dejeneffe M, Meuleman N, et al. Gene expression pattern of functional neuronal cells derived from human bone marrow mesenchymal stromal cells. BMC Genomics.2008,11(9):166-172
116. Smith W. Expression cloning of Noggin:a new dorsalizing factor localized to the spemann organizer in Xenopus embryos. Cell.1992,70(5):89-840
117. Valenzuela DM, Rojas E, Le Beau MM, et al. Genomic organization and chromosomal localization of the human and mouse genes encoding the alpha receptor component for ciliary neurotrophic factor. Genomics,1995,25(1): 157-163
118. Lamb TM, Harland RM. Fibroblast growth factor is a direct neural inducer, which combined with noggin fenerates anterior-posterior neural pattern. Development.1995,121(11):3627-3636
119. Borges AC; Marques S; Belo JA.The BMP antagonists cerberus-like and noggin do not interact during mouse forebrain development. Int J Dev Biol.2001, 45(2):441-4
120. Chiba S, Kurokawa MS, Yoshikawa H, et al. Noggin and basic FGF were implicated in forebrain fate and caudal fate, respectively, of the neural tube-like structures emerging in mouse ES cell culture. Exp Brain Res,2005,163:86-99.
121. Pere MF, Andrade J, Houssami S, et al. Regulation of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin. J Cell Sci,2004,117:1269-1280.
122. Chen HL, Lein PJ, Wang JY, et al. Expression of bone morphogenetic proteins in the brain during normal aging and in 6-hydroxydopamine-lesioned animals. Brain Res,2003,944(1):81-90
123. Valenzuela-DM, Economides-AN, Rojas-E, et-al. Identification of mammalian noggin and its expression in the adult nervous system. J-Neurosci. 1995;15(9):6077-84
124. Nakatomi H, Kuriu T, Okabe S, et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell,2002,110(4):429-441
125. Setoguchi T, Nakashima K, Takizawa T, et al. Treatment of spinal cord injury by transplantation of fetal neural precursor cells engineered to express BMP inhibitor. Exp Neurol,2004,189(1):33-44
126. Mabie PC, Mehler MF, Kessler JA. Multiple roles of bone morphogenetic protein signaling in the regulation of cortical cell number and phenotype. J Neurosci.1999; 19(16):7077-88
127. Gross RE, Mehler MF, Mabie PC, et al. Promotion of astroglial lineage commitment from mammalian subventricular zone progenitor cells by bone morphogenetic proteins. Neuron,1996,17:1-20
128. Lim DA, Tramontin AD, Trevejo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron.2000,28(3):713-2
129. Makoto Y, Takumi T, Wataru O, et al. Fate alteration of neuroepithelial cells from neurogenesis to astrocytogenesis by mbone morphogenetic proteins. Neuroscience,2001,41:391-396
130. Nakashima K, Takizawa T, Ochiai W, et al. BMP2-mediated alteration in the developmental pathway of fetal mouse brain cells from neurogenesis to mastrocytogenesis. Proc Natl Acad Sci USA.2001,98(10):5868-73
131. Liu W, Ren C, Shi J, et al. Characterization of the functionally related sites in the neural inducing gene noggin. Biochem Biophys Res Commun.2000,270(1): 293-7
132. Daniel A, Lim AD, Jose M, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron,2000,283:713-726
133. Reddi AH. Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development:noggin, chordin and DAN. Arthritis Res,2001,3(1):1-5
134. Wita SE, Sato SM. XIPOU 2 is a potential regulator of Spemann's Organizer. Development.1997,124(6):1179-89
135. McLaren A. A scientist's view of the ethics of human embryonic stem cell research. Cell Stem Cell.2007 Jun 7;1(1):23-6
136. Cai YF, Zhen ZJ, Min J. Selection, proliferation and differentiation of bone marrow-derived liver stem cells with a culture system containing cholestatic serum in vitro. World J Gastroenterol,2004,10(22):3308-3312
137. Woodbury D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res,2000,61(4):364-370
138. Brazelton TR, Rossi FM, Keshet GI, et al. From marrow to brain:expression of neuronal phenotypes in adult mice. Science,2000,290(5467):1775-1779
139. Chen L, Li Y, Wang L. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke,2001,32: 1005-1011
140. Li Y, Chopp M, Chen J,et al. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab,2000,20:1311-1319
141. Li Y, Chen J, Wang L, et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett,2001,316(2):67-70.
142. Chen X,Kata Kowski M,Li Y, et al. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts:growth factor production. J Neurosci Res,2002,69 (5):687-691.
143. Crigler L, Robey R C, Asawachaicharn A, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol,2006,198(1):54-64.
144. Phinney D G, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des,2005,11(10):1255-1265.
145. Brinton R D. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease:Recent insight and remaining challenges. Learning Memory,2001,8:121-133.
146. Kafitz K W, Rose C R, Thoenen H, et al. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature,1999,401:918-921.
147. Fallon J, Reid S, Kinyamu R, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci USA,2000,97(26):14686-146911.
148. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine d3 receptor expression and triggers behavioral sensitization. Nature,2001,411:86-89.
149. Batchelor P E, Liberatore G T, Porrit M J, et al. Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injur. European Journal of Neuroscience, 2000,12(10):3462-3468
150. Stach RW, Garian N, Olender EJ.Biological activity of the beta nerve growth factor:the effect of various added proteins. J Neurochem,1979,33(1),257-261.
151. Cheng B, Mattson MP. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res,1994,640(1):56-67
152. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci,2001,24,1217-1281
153. Kondo T, Raff MC. A role for Noggin in the development of oligodendrocyte recursor cells. Develop Biol,2004,267:242-251
154. Castellanos-Ortega MR, Cruz-Aguado R, et al. Nerve growth factor: possibilities and limitations of its clinical application. Rev Neurol,1999,29(5),439-447.
155. Lim DA, Tramontin AD, Trevejo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron,2000,28:713-726
156. Zhao LR, Duan WM, Reyes M, et al. Human bone marrow stem cells exhibit neural phenotypes and ameliaorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol,2002,174(1):11-20
157. Azizi SA, Stokes D, Augelli BJ, et al. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats similarities to astrocyte grafts. Proc Natl Acad Sci USA,1998;95(7):3908-13.
158. Hellmann MA, Panet H, Barhum Y, et al. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett,2006,395:124-128
159. Pavon-Fuentes N, Blanco-Lezcano L, Marinez-Martin L, et al. Stromal cell transplant in 6-OHDA lesion model. Rev Neurol,2004,39 (4):326-334
160. Lee JB, Kuroda S, Shichinohe H, et al. A pre-clinical assessment model of rat autogeneic bone marrow stromal cell transplantation into the central nervous system. Brain Res Protoc,2004,14(1):37-44
161. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc NatlAcad Sci USA,1999,96(19):1071-6.
162. Brazelton TR, Rossi FMV, Keshet GI, et al. Form marrow to brain:expression of neuronal phenotypes in adult mice. Science,2000,290(5497):1775-1779
163. Mezey E, Key S, et al. Transpalnted bone marrow generates new neurons in human brains. Proc Natl Acad Sci USA,2003,100(3),1364-9.
164. Choong PF, Mok PL, Cheong SK,et al. Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy.2007,9(2):170-83.
165. Lim DA, Tramontin AD, Trevejo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron.2000,28(3):713-2
166. Mabie PC; Mehler MF; Kessler JA. Multiple roles of bone morphogenetic protein signaling in the regulation of cortical cell number and phenotype. J Neurosci.1999,19(16):7077-88
1. Friedenstein A J, Gorskaja J F, Kulagina N N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol,1976,4:267-272.
2. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells:invitro cultivation transplantation in diffusion chambers. Cell Tissue,1987, 20:263
3. Pittenger M F, Mackay A M, Jaisdwal S C, et al. Multilineage potential of adult human mesemchymal stem cells. Science,1999,284(5411):143-147
4. Zhang Y, Lin HK, Frimberger D, et al. Growth of bone marrow stromal cells on small intestinal submucosa:an alternative sell source for tissue engineered bladder. BJU Int,2005,96(7):1120-1125
5. Sasaki DT, Tichenor EH, Lopez F, et al. Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. J Hematother.1995,4(6):503-14.
6. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol,2000,164(2):247-256
7. Deryugina EI, Muller-sieburg CE. Stromal cells in longterm cultures:keys to the elucidation of hematopoietic development. Crit Rev Immunol,1993,13:115-121
8. Kitano Y, Radu A, Shabban A, et al. Selection, enrichment, and culture expansion of murine mesenchymal progenitor cells by retroviral transduction of cycling adherent bone marrow cells. Exp Hemato,2000,28(12):1460-1469
9. Lennon D P, Haynesworth S E, Young R G et al. A chemically defined medium supprots in vitro proliferation and maintains the osteochondral potential of rat marrow2derived mesenchymal stem cells. Exp Cell Res,1995,219 (1):211-222
10. Bruder S P, Jaiswal N, Haynesworth S E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subculativation and following cryopreservation. Journal of Cellular Biochemistry, 1997,64:278-294
11. Jachson L, Jones DR, Scotting P, et al, Adult mesenchymal stem cells: Differentiation potential and therapeutic applications. J Postgrad Med,2007, 53(2):121-127
12. Halleux C, Sottile V, Gasser J A et al. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskel Neuron Interact,2001,2(1):71-76
13. Woodburry D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res,2000,61:3642370.
14. Kohyama J, Abe H, Shimazaki T, et al. Brain from bone:efficient "meta-differentiation" of marrow stroma-derive mature osteoblasts to neurons with Noggin or a demethylating agent. Differentiation,2001,68:235-243.
15. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA,1999,96 (19):10711-10716.
16. Brazelton TR, Rossi FM, Keshet GI, et al. From marrow to brain:expression of neuronal phenotyes in adult mice. Science,2000,290:1775-1779
17. Mezey E, Chandross KJ, Harta G, et al. Turning blood into brain:cells bearing neuronal antigens generated in vivo from bone marrow. Science,2000, 290:1779-1782.
18. Yano S, Kuroda S, Lee JB, et al. In vivo fluorescence tracking of bone marrow s tromal cells transplanted into a pneumatic injury model of rat spinal cord. J Neurotrauma,2005,22(8):907-918
19. Chopp M, Zhang XH, Li Y, et al. Spinal cord injury in rat:treatment with bone marrow stromal cell transplantation. Neuroreport,2000,11 (13):3001-3005
20. Mahmood A, Lu D, Chopp M. Marrow stromal cell trasplantation after traumatic brain injury promotes celluar proliferation within the brain. Neurosurgery,2004, 55(5):1185-1193
21. Shichinohe H, Kuroda S, Lee JB, et al. In vivo tracking of bone marrow stromal cells transplanted into mice cerebral infarct by fluorescence optical imaging. Brain Res Protoc,2004,13(3):166-175
22. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol,2002,30:42-48.
23. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood,2002,99:3838-3843.
24. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood,2003,101:3722-3729.
25. Suzuki H, Taguchi T, Tanaka H, et al. Neurospheres induced frombone marrow stromal cells are multipotent for differentiation into neuron, as trocyte, and oligodendrocyte phenotypes. Biochem Biophy Res Commun,2004, 322(3):918-922
26. Liu S, Yu Y, An H, et al. Cloning and identification of a novel ubiquitin-like protein, BMSC-UbP from human bone marrow stromal cells. Immunol Lett, 2003,86(2):169-175
27. Li Y, Chen J, Wang L, et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett,2001,316(2):67-70.
28. Chen X, Katakowski M, Li Y, et al. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts:growth factor production. J Neurosci Res,2002,69(5):687-691.
29. Crigler L, Robey RC, Asawachaicharn A, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol,2006,198:54-64.
30. Hellmann MA, Panet H, Barhum Y, et al. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett,2006,395:124-128
31. Pavon-Fuentes N, Blanco-Lezcano L, Marinez-Martin L, et al. Stromal cell transplant in 6-OHDA lesion model. Rev Neurol,2004,39 (4):326-334
32. Lee JB, Kuroda S, Shichinohe H, et al. A pre-clinical assessment model of rat autogeneic bone marrow stromal cell transplantation into the central nervous system. Brain Res Protoc,2004,14(l):37-44
33. Shintani A, Nakao N, Kakishita K, Itakura T. Protection of dopamine neurons by bone marrow stromal cells. Brain Res,2007,1186:48-55.
34. Yi L, J 1 Chen, Wang L, et al, Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett,2001;316(2):67-70.
35. Sinhaa R, Racetteb B, Perlmutter JS, et al. Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.Parkinsonism relat disord 2005; 11(6):341-347
36. Purisai MG, McCormack AL, Langs ton WJ, et al. Alpha-Synuclein expres sion in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 2005;20(3):898-906
37. Bonin M, Poths S, Osaka H, et al. Microarray expression analysis of gad mice implicates involvement of Parkinson's disease as sociated UCH-L1 in multiple metabolic pathways. Brain Res Mol Brain Res,2004;126(1):88-97
38. YAMADA H, DEZAWA M, SHIMAZU S, et al. Transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease[J]. Ann Neurol,2003;54(3):352-359.
39. WANG X J, LIU W G, ZHANG Y H, et al. Effect of transplantation of c17.2 cells transfected with interleukin-10 gene on intracerebral immune response in rat model of Parkinson's disease. Neurosci Lett,2007,423(2):95-99.
40. Torresa EM, Monvillea C, Lowensteinb PR, et al. In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. Brain Res,2005;137(1-2):1-10
41. SchwarzE J, Reger R L, Alexander G M, et al. Rat marrow stromal cells rapidly transduced with a self-inactivating retrovirus synthesize L-DOPA in vitro. Gene Ther,2001;8(16):1214-1223.
42. Park KW, Eglitis MA, Mouradian MM. Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res,2001;40(4): 315-323
43. Schwarz E J, Alexander G M, Prockop D J, et al. Multipotential marrow stromal cells transduced to produce L-DOPA engraftment in a rat model of Parkinson disease. Hum Gene Ther,1999,10(15):2539-2549.
44. Lu L, Zhao C, Liu Y, et al. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res Protoc,2005,15(1):46-51.
45. Park S, Kim EY, Ghil GS, et al. Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease. Neurosci Lett,2003;353(2):91-94
46. Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administation of ischemia in rats. Stroke 2001;32(4):1005-1011
47. Ye M, Wang XJ, Zhang YH, Lu GQ, Liang L, Xu JY, Chen SD. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Brain Res,2007,1142:206-216.
48. Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy, 2008,10:340-352.
49. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG.. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol, 2006,198:54-64.
50. Mahmood A, Lu D, Chopp M. Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. J Neurotrauma,2004,21:33-39.
51. Kitada M, Dezawa M. Neural repair. Nippon Rinsho,2008,66(5):921-925.
2. Ahn TB,Kim Jm,Kwon KM,et al. Survival and migration of transplanted neural stem cell-derived dopamine cells in the brain of parkinsonian rat. Int J Neurosci,2004,114(5):575-585.
3. Yasuhara T, Shingo T, Muraoka K,et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg, 2005,102(1):80-89.
4. Schober A. Classic toxin-induced animal models of Parkinson's disease:6-OHDA and MPTP. Cell Tissue Res,2004,318 (1):215-224.
5. Langston JW, Forno LS, Testrud J, et al. Evidence of active cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyk-1,2,3,6-tetrahydropyridine exposure. Ann Neurol,1999,46:598-605.
6. Javitch JA,D'Amato RJ,Strittmatter SM,et al. Parkinsonism inducing neurotoxin,N-methyl-4-henyl-1,2,3,6-tetrahydropyridine:uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA,1985,82:2173-2177.
7. Tipton KF, Singer TP. Advances in our understanding of the mechanism of the neurotoxicity of MPTP and related compounds. J Neurochem, 1993,61:1191-1206.
8. Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinemodel of Parkinson's disease. Proc Natl Acad Sci USA,2003,100(10):6145-50.
9. Sriram K, Pai KS, Boyd MR, et al. Evidence for generation of oxidative stress in brain by MPTP:in vitro and in vivo studies in mice. Brain Res,1997,749:44-52.
10. Hantraye P, Varastet M, Peschanski M, et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience,1993,53:169-178.
11. Brooks AI, Chadwick CA, Gelbard HA, et al. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.Brain Res,1999,823:1-10.
12. Shimizu K, Matsubara K, Ohtaki K, et al. Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture. Neurosci Res,2003,46(4):523-532.
13. Takahashi RN, Rogerio R, Zanin M. Maneb enhances MPTP neurotoxicity in mice. Res Commun Chem Pathol Pharmacol,1989,66:167-170.
14. Thiruchelvam M, Richfield EK, Baggs RB, et al. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb:implications for Parkinson's disease. J Neurosci,2000,20:9207-9214.
15. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci,2000,3:1301-1306.
16. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase:an overview. Biochim Biophys Acta,1998,1364(2):222-235.
17. Ben-shachar D, Youdim MB. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem,1991,57(6):2133-2135.
18. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alphasynuclein mice:implications for neurodegenerative disorders. Science,2000,287(5456):1265-1269.
19. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature,2000,404(6776):394-398.
20. Barneroud P, Parmentier S, Mazadier M, et al. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat.Neuroscience,1995,67(4):837-848.
21. Przedvorski S, Levieier M, et al. Dose dependent lesion of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-OHDA. Neuroscience,1995,67:631-647.
22. Olsson M,Nikkhah G,Bentlage C,et al. Forelimb akinesia in the rat Parkinson model:differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.J Neurosci,1995,15(5):3863～3875.
23. Ellenbroek BA, Peeters BW, Honig WM,et al. The paw test:a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology(Berl),1987,93(3):343～348.
24. Montoya CP, Campbell-Hope LJ, Pemberton KD, et al. The"staircase test":a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods,1991,36(2-3):219～228.
25. Cousins MS, Salamone JD. Involvement of ventrolateral striatal dopamine in movement initiation and execution:a microdialysis and behavioral investigation. Neuro science,1996,70(4):849～859.
26. Amalric M, Moukhles H, Nieoullon A, et al. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci,1995,7(5):972～980.
27. Whishaw IQ, Dunnett SB. Dopamine depletion, stimulation or blockade in the rat disrupts spatial navigation and locomotion dependent upon beacon or distal cues. Behav Brain Res,1985,18(1):11～29.
28. Carman LS, Gage FH, Shults CW,. Partial leision of the substantia nigra:relation between extent of lesion and rotational behavior. Brain Res, 1991,553(2);275-283.
29. Perese DA, Ulman J, Viola J, et al. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res,1989,494(2):285-293.
30. Barneoud P, Parmentier S, Mazadier M, et al. Effect s of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat.Neuroscience,1995,67(4):837～848.
31. Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesion of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol,1996,49(3):215-266.
32. Signore AP, Weng Z, Hastings T, et al. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem, 2006,96(2):428-443
33. Evans MJ, Kauman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature.1981;292(9):154.
34. Friedenstein AJ. Precursor cells of mechynocytes. Int Rev Cytol,1968, 47:327-355
35. Pittenger MF, Machay AM, Bech SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science,1999,284(5411):143-147
36. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med,2001, 226(6):507-520
37. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature,2002,418(6893):41-49
38. Cai YF, Zhen ZJ, Min J. Selection, proliferation and differentiation of bone marrow-derived liver stem cells with a culture system containing cholestatic serum in vitro. World J Gastroenterol,2004,10(22):3308-3312
39. Fraser JK, Zhu M, Wulur I. Adipose-derived stem cells. Methods Mol Biol.2008, 449:59-67.
40. Kim SJ, Lee JK, Kim JW, et al. Surface modification of polydimethylsiloxane (PDMS) induced proliferation and neural-like cells differentiation of umbilical cord blood-derived mesenchymal stem cells.J Mater Sci Mater Med.2008,24
41. Caplan AI. Mesenchymal stem cells. J Orthop Res.1991,9(5):641-650
42. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells:invitro cultivation transplantation in diffusion chambers. Cell Tissue, 1987,20:263
43. Pittenger M F, Mackay A M, Jaisdwal S C, et al. Multilineage potential of adult human mesemchymal stem cells[J]. Science,1999,284(5411):143-147
44. Zhang Y, Lin HK, Frimberger D, et al. Growth of bone marrow stromal cells on small intestinal submucosa:an alternative sell source for tissue engineered bladder. BJU Int,2005,96(7):1120-1125
45. Sasaki DT, Tichenor EH, Lopez F, et al. Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. J Hematother.1995 Dec;4(6):503-14.
46. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol,2000,164(2):247-256
47. Deryugina EI, Muller-sieburg CE. Stromal cells in longterm cultures:keys to the elucidation of hematopoietic development. Crit Rev Immunol,1993,13:115-121
48. Kitano Y, Radu A, Shabban A, et al. Selection, enrichment, and culture expansion of murine mesenchymal progenitor cells by retroviral transduction of cycling adherent bone marrow cells. Exp Hemato,2000,28(12):1460-1469
49. David C C, Reiner C, Carla M et al. Rapid expansion of recycling stem cells in cultrues of plastic2adherent cells from human bone marrow. Proc Natl Acad Sci USA,2000,97(7):3213-3218.
50. Bruder S P, Jaiswal N, Haynesworth S E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subculativation and following cryopreservation. J Cell Biochem,1997,64:278-294.
51. Lennon D P, Haynesworth S E, Young R G, et al. A chemically defined medium supprots in vitro proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells. Exp Cell Res,1995,219(1):211-222.
52. Jachson L, Jones DR, Scotting P, et al. Adult mesenchymal stem cells: Differentiation potential and therapeutic applications. J Postgrad Med,2007, 53(2):121-127
53. Gregory CD, Devitt A, etal. CD14 and apoptosis. Apoptosis 1999,4:11-20
54. Kranse DS, Fackler MJ, Civin Cl, et al. CD34:Structure, biology, and clinical utility. Blood,1996; 87:1-13
55. Haynes BF et al. Cancer Cells,1991;3(9):347-350//Korfuruta et al.Clin Cancer Res,1998,4:21-29
56. Hou M, et al. Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats. Int J Cardiol.2007,115(2): 220-8
57. M Dominicil,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy.2006,8(4):315-317
58. Mai Hou, et al. Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats. International Journal of Cardiology.2007,115 () 220-228
59. Heterogeneity of stromal precursor cells isolated from rat bone marrow. Tsitologiia.2007,49(1):40-47
60. Yamaguchi T, Chattopadhyay N, Kifor O, et al. Extracellular calcium (Ca2+(O))-sensing receptor in a murine bone marrow-derived stromal cell line (ST2):potential mediator of the actions of Ca2+(O) on the function of ST2 cells. Endocrinology,1998,139:3561-38568
61. Tang QQ, Jiang MS, Lane MD. Repressive effect of Spl on the C/EBPalpha gene promoter:role in adipocyte differentiation. Mol Cell Biol,1999,19:4855-4865
62. Klemm DJ, Roesler WJ, Boras T, et al. Insulin stimulates c AMP-response element binding protein activity in JepG2 and 3T3-L1 cell lines. J Biol Chem, 1998,273:917-923
63. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferators-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs, J Biol Chem,1997,272:3406-3410
64. Varga F, Luegmayr E, Fratzl-Zelman N, et al. Tri-iodothyronine inhibits multilayer formation of the osteoblastic cell line, MC3T3-E1, by promoting apoptosis. J Endocrinol,1999,160:57-65
65. Coelho MJ, Fernandes MH. Human bone cell cultures in biocompatibility testing. Part Ⅱ:effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation. Biomaterials,2000,21:1095-1102
66. Otsuka E, Yamaguchi A, Hirose S, et al. Characterization of osteoblastic differentiation of stromal cell line ST2 that is induced by ascorbic acid. Am J Physiol,1999,277:C132-138
67. Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear location signals for nonviral gene transfer. Gen Ther,2002,9:157-167
68. Mh C, Byrne BJ, Flotte TR. Virus-base gene delivery system. Clin Pharmacokinet, 2002,41:901-911
69. Kurai T, Shimada T. Recombinant adeno-associated virus-mediated gene delivery to the central nervous system. J Nippon Med Sch,2007; 74(3):188-189.
70. Kozlowski M, Olson DE, Rubi n J,et al. Adenoassociated viral delivery of a metabolically regulated insulin transgene to hepatocytes. Mol Cell Endocrino,2007; 273(1-2);6-15.
71. Rabie AB, Dai J, Xu R. Recombinant AAV- mediated VEGF gene therapy induces mandibular condylar growth. Gene Ther,2007; 14(12):972-980.
72. Yeh P, Perricaudet M. Advances in adenoviral vectors:From genetic engineering to their biology. FASEB J,1997,11:615-623
73. Balci b, Yilmaz O. Extent of coronary collateral vessel decrease with advanced age. Acta Cardiol.2004,59(4):431-434
74. Rissanen TT, Rutanen J, Yla-Herttuala S. Gene transfer for therapeutic vascular growth in growth in myocardial and peripheral ischemia. Adv Genet.2004,52: 117-164
75. Monaham PE, Samulski RJ. Adeno-associated virus vectors for gene therapy, more pros than cons? Mol Med Today,2000,6:433-440
76. LS Young, V Mautner. The promise and potential hazards of adenovirus gene therapy. Gut,2001,48:733-736
77. Menei P, Montero-Menei C, Whittenore SR, et al. Schwann cells genetically modified to secrete human BDNF promote enhanced axonal regrowth across transected adult rat spinal cord. Eur J Neurosci,1998,10:607-621
78. Le BK, Tammik C, Rosendahl K, et al. HLA expression and immunologic proterties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol,2003,31:890-896
79. Le BK, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol,2003,57:11-20
80. Chen ZM, O'Shaughnessy MJ, Gramaglia I, et al. IL-10 and TGF-beta induce alloreactive CD4+ CD25- T cells to acquire regulatory cell function. Blood,2003, 101:5076-5083
81. Valero A, Post JN, van Nieuwkasteele JW, et al. Gene transfer and protein dynamics in stem cells using single cell electroporation in a microfluidic device. Lab Chip,2008,8(1):62-7
82. Meinel L, Hofmann S, Betz O,et al. Osteogenesis by human mesenchymal stem cells cultured on silk biomaterials:comparison of adenovirus mediated gene transfer and protein delivery of BMP-2. Biomaterials.2006,27(28):4993-5002
83. Kyriakou CA, Yong KL, Benjamin R,et al. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med.2006,8(3):253-64
84. Shih CH, Cheng YL, Song KS. Lineage differentiation-associated loss of adenoviral susceptibility and coxsachie-adenovirus receptor expression in human mesenchymal stem cell. Stem cells,2004,22:1321-1329
85. Tsien RY. The green fluorescent protein. Annu Rev Biochem,1998,67:509-544
86. Chalfie M, Tu Y, Euskirhen G, et al. Green fluorescent protein as a marker for gene expression. Science,1994,263:802-805
87. Hong SS, Karayan L, Tournier J, et al. Adenovirus type 5 fiber knob binds to MHC class I a 2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J,1997,16:2291-2306
88. Walters RW, Grunst T, Bergelson JM, et al. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem,1999,274:10219-10226
89. Ss-eisler A, Falck-pedersen E, Alvira M, et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA,1993,90:11498-11502
90. Frey M, Hachett NR, Bergelson JM, et al. High-efficiency gene transfer into exvivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors. Blood,1998,91:2781-2792
91.Halleux C, Sottile V, Gasser J A, et al. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskel Neuron Interact,2001,2(1):71-76.
92. Tropel P, Platet N, Platel JC, et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells.Stem Cells.2006,24(12):2868-76
93. Wislet-Gendebien S, Wautier F, Leprince P, et al. Astrocytic and neuronal fate of mesenchymal stem cells expressing nestin. Brain Res Bull.2005,68(1-2):95-102
94. Wislet-Gendebien S, Hans G, Leprince P, et al. Plasticity of cultured mesenchymal stem cells:switch from nestin-positive to excitable neuron-like phenotype.Stem Cells.2005,23(3):392-402
95. Song S, Song S, Zhang H, et al. Comparison of neuron-like cells derived from bone marrow stem cells to those differentiated from adult brain neural stem cells. Stem Cells Dev.2007,16(5):747-56
96. Kohyama et al. Brain from bone:Efficent'meta-differentiation'of marrow stromal-derived cell mature osteoblasts to neurons with Noggin or demythylating agent. Differentiation,2001(68):235-244
97. Woodbury D, Schwarz EJ, Prochop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res,2000,61(4):364-370
98. Suzuki H, Taguchi T, Tanaka H, et al. Neurospheres induced from bone marrow stromal cells are multipotent for differentiation into neuron, astrocyte, and oligodendrocyte phenotypes. Bioche Biophys Res Commun,2004,322:918-922.
99. Jori FP, Napolitano MA, Melone MA, et al. Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J CellBiochem,2005, 94:645-655
100. Lei Z, Yongda L, Jun M, Yingyu S, et al. Culture and neural differentiation of rat bone marrow mesenchymal stem cells in vitro.Cell Biol Int.2007,31(9): 916-23
101. Tao H, Rao R, Ma DD.Cytokine-induced stable neuronal differentiation of human bone marrow mesenchymal stem cells in a serum/feeder cell-free condition.Dev Growth Differ.2005,47(6):423-33
102. Kim S, Honmou O, Kato K, et al. Neural differentiation potential of peripheral blood and bone marrow derived precursor cells. Brain Res. 2006, 1123(1):27-33
103. Long X, Olszewski M, Huang W. Neural cell differentiation in vitro from adult human bone marrow mesenchymal stem cells. Stem Cells Dev.2005,14(1): 65-9
104. Hoener-MC, Hewirr E, Connner M, et al. Nerve growth factor (NGF) content in adult rat brain tissues is several-fold higher than generally reported and id largely associated with sedimentable fractions. Brain Res,1996,728(1):47-56
105. Levi MR. The nerve growth factor 35 years later. Science,1987,237: 1154-1158
106. Covaceuszach S, Cattaneo A, Lamba D. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody M AC 13:a structural insight. Proteins,2005,58(3):717-72
107. Bilderback TR, Gazula VR, Dobrowsky RT. Phosphoinositide 3-kinase regulates crosstalk between Trk A tyrosine kinase and p75 (NTR)-dependent sphingolipid signaling pathways. J Neurochem,2001,76(5):1540-1551
108. Ibanez CF. Structure-function relationships in the neurotrophin family. J Neurobiol,1994,25:1349-1361
109. Yuen EC, Mobley WC. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol,1996,40:346-354
110. Yoon SO, Casaccia BP, Carter B, et al. Competitive signaling between TrkA and P75 nerve growth factor receptors determines cell survival. J Neurosci,1998, 18:3273-3279
111. Baker SJ, Reddy EP. Transducers of life and death:TNF receptor superfamily and associated proteins. Oncogene,1996,12:1-9
112. Frade JM, Rodriguez TA, Barde YA. Induction of cell death by endogenous NGF through its P75 receptor. Nature,1996,383:166-172
113. Anton ES. Nerve growth factor and its low-affinity receptor promote Schwann cell migration. Proc Natl Acad Sci USA,1994,91:2795-2799
114. Choong PF, Mok PL, Cheong SK, et al. Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy.2007,9(2):170-83
115. Tondreau T, Dejeneffe M, Meuleman N, et al. Gene expression pattern of functional neuronal cells derived from human bone marrow mesenchymal stromal cells. BMC Genomics.2008,11(9):166-172
116. Smith W. Expression cloning of Noggin:a new dorsalizing factor localized to the spemann organizer in Xenopus embryos. Cell.1992,70(5):89-840
117. Valenzuela DM, Rojas E, Le Beau MM, et al. Genomic organization and chromosomal localization of the human and mouse genes encoding the alpha receptor component for ciliary neurotrophic factor. Genomics,1995,25(1): 157-163
118. Lamb TM, Harland RM. Fibroblast growth factor is a direct neural inducer, which combined with noggin fenerates anterior-posterior neural pattern. Development.1995,121(11):3627-3636
119. Borges AC; Marques S; Belo JA.The BMP antagonists cerberus-like and noggin do not interact during mouse forebrain development. Int J Dev Biol.2001, 45(2):441-4
120. Chiba S, Kurokawa MS, Yoshikawa H, et al. Noggin and basic FGF were implicated in forebrain fate and caudal fate, respectively, of the neural tube-like structures emerging in mouse ES cell culture. Exp Brain Res,2005,163:86-99.
121. Pere MF, Andrade J, Houssami S, et al. Regulation of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin. J Cell Sci,2004,117:1269-1280.
122. Chen HL, Lein PJ, Wang JY, et al. Expression of bone morphogenetic proteins in the brain during normal aging and in 6-hydroxydopamine-lesioned animals. Brain Res,2003,944(1):81-90
123. Valenzuela-DM, Economides-AN, Rojas-E, et-al. Identification of mammalian noggin and its expression in the adult nervous system. J-Neurosci. 1995;15(9):6077-84
124. Nakatomi H, Kuriu T, Okabe S, et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell,2002,110(4):429-441
125. Setoguchi T, Nakashima K, Takizawa T, et al. Treatment of spinal cord injury by transplantation of fetal neural precursor cells engineered to express BMP inhibitor. Exp Neurol,2004,189(1):33-44
126. Mabie PC, Mehler MF, Kessler JA. Multiple roles of bone morphogenetic protein signaling in the regulation of cortical cell number and phenotype. J Neurosci.1999; 19(16):7077-88
127. Gross RE, Mehler MF, Mabie PC, et al. Promotion of astroglial lineage commitment from mammalian subventricular zone progenitor cells by bone morphogenetic proteins. Neuron,1996,17:1-20
128. Lim DA, Tramontin AD, Trevejo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron.2000,28(3):713-2
129. Makoto Y, Takumi T, Wataru O, et al. Fate alteration of neuroepithelial cells from neurogenesis to astrocytogenesis by mbone morphogenetic proteins. Neuroscience,2001,41:391-396
130. Nakashima K, Takizawa T, Ochiai W, et al. BMP2-mediated alteration in the developmental pathway of fetal mouse brain cells from neurogenesis to mastrocytogenesis. Proc Natl Acad Sci USA.2001,98(10):5868-73
131. Liu W, Ren C, Shi J, et al. Characterization of the functionally related sites in the neural inducing gene noggin. Biochem Biophys Res Commun.2000,270(1): 293-7
132. Daniel A, Lim AD, Jose M, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron,2000,283:713-726
133. Reddi AH. Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development:noggin, chordin and DAN. Arthritis Res,2001,3(1):1-5
134. Wita SE, Sato SM. XIPOU 2 is a potential regulator of Spemann's Organizer. Development.1997,124(6):1179-89
135. McLaren A. A scientist's view of the ethics of human embryonic stem cell research. Cell Stem Cell.2007 Jun 7;1(1):23-6
136. Cai YF, Zhen ZJ, Min J. Selection, proliferation and differentiation of bone marrow-derived liver stem cells with a culture system containing cholestatic serum in vitro. World J Gastroenterol,2004,10(22):3308-3312
137. Woodbury D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res,2000,61(4):364-370
138. Brazelton TR, Rossi FM, Keshet GI, et al. From marrow to brain:expression of neuronal phenotypes in adult mice. Science,2000,290(5467):1775-1779
139. Chen L, Li Y, Wang L. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke,2001,32: 1005-1011
140. Li Y, Chopp M, Chen J,et al. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab,2000,20:1311-1319
141. Li Y, Chen J, Wang L, et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett,2001,316(2):67-70.
142. Chen X,Kata Kowski M,Li Y, et al. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts:growth factor production. J Neurosci Res,2002,69 (5):687-691.
143. Crigler L, Robey R C, Asawachaicharn A, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol,2006,198(1):54-64.
144. Phinney D G, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des,2005,11(10):1255-1265.
145. Brinton R D. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease:Recent insight and remaining challenges. Learning Memory,2001,8:121-133.
146. Kafitz K W, Rose C R, Thoenen H, et al. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature,1999,401:918-921.
147. Fallon J, Reid S, Kinyamu R, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci USA,2000,97(26):14686-146911.
148. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine d3 receptor expression and triggers behavioral sensitization. Nature,2001,411:86-89.
149. Batchelor P E, Liberatore G T, Porrit M J, et al. Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injur. European Journal of Neuroscience, 2000,12(10):3462-3468
150. Stach RW, Garian N, Olender EJ.Biological activity of the beta nerve growth factor:the effect of various added proteins. J Neurochem,1979,33(1),257-261.
151. Cheng B, Mattson MP. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res,1994,640(1):56-67
152. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci,2001,24,1217-1281
153. Kondo T, Raff MC. A role for Noggin in the development of oligodendrocyte recursor cells. Develop Biol,2004,267:242-251
154. Castellanos-Ortega MR, Cruz-Aguado R, et al. Nerve growth factor: possibilities and limitations of its clinical application. Rev Neurol,1999,29(5),439-447.
155. Lim DA, Tramontin AD, Trevejo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron,2000,28:713-726
156. Zhao LR, Duan WM, Reyes M, et al. Human bone marrow stem cells exhibit neural phenotypes and ameliaorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol,2002,174(1):11-20
157. Azizi SA, Stokes D, Augelli BJ, et al. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats similarities to astrocyte grafts. Proc Natl Acad Sci USA,1998;95(7):3908-13.
158. Hellmann MA, Panet H, Barhum Y, et al. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett,2006,395:124-128
159. Pavon-Fuentes N, Blanco-Lezcano L, Marinez-Martin L, et al. Stromal cell transplant in 6-OHDA lesion model. Rev Neurol,2004,39 (4):326-334
160. Lee JB, Kuroda S, Shichinohe H, et al. A pre-clinical assessment model of rat autogeneic bone marrow stromal cell transplantation into the central nervous system. Brain Res Protoc,2004,14(1):37-44
161. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc NatlAcad Sci USA,1999,96(19):1071-6.
162. Brazelton TR, Rossi FMV, Keshet GI, et al. Form marrow to brain:expression of neuronal phenotypes in adult mice. Science,2000,290(5497):1775-1779
163. Mezey E, Key S, et al. Transpalnted bone marrow generates new neurons in human brains. Proc Natl Acad Sci USA,2003,100(3),1364-9.
164. Choong PF, Mok PL, Cheong SK,et al. Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy.2007,9(2):170-83.
165. Lim DA, Tramontin AD, Trevejo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron.2000,28(3):713-2
166. Mabie PC; Mehler MF; Kessler JA. Multiple roles of bone morphogenetic protein signaling in the regulation of cortical cell number and phenotype. J Neurosci.1999,19(16):7077-88
1. Friedenstein A J, Gorskaja J F, Kulagina N N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol,1976,4:267-272.
2. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells:invitro cultivation transplantation in diffusion chambers. Cell Tissue,1987, 20:263
3. Pittenger M F, Mackay A M, Jaisdwal S C, et al. Multilineage potential of adult human mesemchymal stem cells. Science,1999,284(5411):143-147
4. Zhang Y, Lin HK, Frimberger D, et al. Growth of bone marrow stromal cells on small intestinal submucosa:an alternative sell source for tissue engineered bladder. BJU Int,2005,96(7):1120-1125
5. Sasaki DT, Tichenor EH, Lopez F, et al. Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. J Hematother.1995,4(6):503-14.
6. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol,2000,164(2):247-256
7. Deryugina EI, Muller-sieburg CE. Stromal cells in longterm cultures:keys to the elucidation of hematopoietic development. Crit Rev Immunol,1993,13:115-121
8. Kitano Y, Radu A, Shabban A, et al. Selection, enrichment, and culture expansion of murine mesenchymal progenitor cells by retroviral transduction of cycling adherent bone marrow cells. Exp Hemato,2000,28(12):1460-1469
9. Lennon D P, Haynesworth S E, Young R G et al. A chemically defined medium supprots in vitro proliferation and maintains the osteochondral potential of rat marrow2derived mesenchymal stem cells. Exp Cell Res,1995,219 (1):211-222
10. Bruder S P, Jaiswal N, Haynesworth S E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subculativation and following cryopreservation. Journal of Cellular Biochemistry, 1997,64:278-294
11. Jachson L, Jones DR, Scotting P, et al, Adult mesenchymal stem cells: Differentiation potential and therapeutic applications. J Postgrad Med,2007, 53(2):121-127
12. Halleux C, Sottile V, Gasser J A et al. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskel Neuron Interact,2001,2(1):71-76
13. Woodburry D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res,2000,61:3642370.
14. Kohyama J, Abe H, Shimazaki T, et al. Brain from bone:efficient "meta-differentiation" of marrow stroma-derive mature osteoblasts to neurons with Noggin or a demethylating agent. Differentiation,2001,68:235-243.
15. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA,1999,96 (19):10711-10716.
16. Brazelton TR, Rossi FM, Keshet GI, et al. From marrow to brain:expression of neuronal phenotyes in adult mice. Science,2000,290:1775-1779
17. Mezey E, Chandross KJ, Harta G, et al. Turning blood into brain:cells bearing neuronal antigens generated in vivo from bone marrow. Science,2000, 290:1779-1782.
18. Yano S, Kuroda S, Lee JB, et al. In vivo fluorescence tracking of bone marrow s tromal cells transplanted into a pneumatic injury model of rat spinal cord. J Neurotrauma,2005,22(8):907-918
19. Chopp M, Zhang XH, Li Y, et al. Spinal cord injury in rat:treatment with bone marrow stromal cell transplantation. Neuroreport,2000,11 (13):3001-3005
20. Mahmood A, Lu D, Chopp M. Marrow stromal cell trasplantation after traumatic brain injury promotes celluar proliferation within the brain. Neurosurgery,2004, 55(5):1185-1193
21. Shichinohe H, Kuroda S, Lee JB, et al. In vivo tracking of bone marrow stromal cells transplanted into mice cerebral infarct by fluorescence optical imaging. Brain Res Protoc,2004,13(3):166-175
22. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol,2002,30:42-48.
23. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood,2002,99:3838-3843.
24. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood,2003,101:3722-3729.
25. Suzuki H, Taguchi T, Tanaka H, et al. Neurospheres induced frombone marrow stromal cells are multipotent for differentiation into neuron, as trocyte, and oligodendrocyte phenotypes. Biochem Biophy Res Commun,2004, 322(3):918-922
26. Liu S, Yu Y, An H, et al. Cloning and identification of a novel ubiquitin-like protein, BMSC-UbP from human bone marrow stromal cells. Immunol Lett, 2003,86(2):169-175
27. Li Y, Chen J, Wang L, et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett,2001,316(2):67-70.
28. Chen X, Katakowski M, Li Y, et al. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts:growth factor production. J Neurosci Res,2002,69(5):687-691.
29. Crigler L, Robey RC, Asawachaicharn A, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol,2006,198:54-64.
30. Hellmann MA, Panet H, Barhum Y, et al. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett,2006,395:124-128
31. Pavon-Fuentes N, Blanco-Lezcano L, Marinez-Martin L, et al. Stromal cell transplant in 6-OHDA lesion model. Rev Neurol,2004,39 (4):326-334
32. Lee JB, Kuroda S, Shichinohe H, et al. A pre-clinical assessment model of rat autogeneic bone marrow stromal cell transplantation into the central nervous system. Brain Res Protoc,2004,14(l):37-44
33. Shintani A, Nakao N, Kakishita K, Itakura T. Protection of dopamine neurons by bone marrow stromal cells. Brain Res,2007,1186:48-55.
34. Yi L, J 1 Chen, Wang L, et al, Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett,2001;316(2):67-70.
35. Sinhaa R, Racetteb B, Perlmutter JS, et al. Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.Parkinsonism relat disord 2005; 11(6):341-347
36. Purisai MG, McCormack AL, Langs ton WJ, et al. Alpha-Synuclein expres sion in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 2005;20(3):898-906
37. Bonin M, Poths S, Osaka H, et al. Microarray expression analysis of gad mice implicates involvement of Parkinson's disease as sociated UCH-L1 in multiple metabolic pathways. Brain Res Mol Brain Res,2004;126(1):88-97
38. YAMADA H, DEZAWA M, SHIMAZU S, et al. Transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease[J]. Ann Neurol,2003;54(3):352-359.
39. WANG X J, LIU W G, ZHANG Y H, et al. Effect of transplantation of c17.2 cells transfected with interleukin-10 gene on intracerebral immune response in rat model of Parkinson's disease. Neurosci Lett,2007,423(2):95-99.
40. Torresa EM, Monvillea C, Lowensteinb PR, et al. In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. Brain Res,2005;137(1-2):1-10
41. SchwarzE J, Reger R L, Alexander G M, et al. Rat marrow stromal cells rapidly transduced with a self-inactivating retrovirus synthesize L-DOPA in vitro. Gene Ther,2001;8(16):1214-1223.
42. Park KW, Eglitis MA, Mouradian MM. Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res,2001;40(4): 315-323
43. Schwarz E J, Alexander G M, Prockop D J, et al. Multipotential marrow stromal cells transduced to produce L-DOPA engraftment in a rat model of Parkinson disease. Hum Gene Ther,1999,10(15):2539-2549.
44. Lu L, Zhao C, Liu Y, et al. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res Protoc,2005,15(1):46-51.
45. Park S, Kim EY, Ghil GS, et al. Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease. Neurosci Lett,2003;353(2):91-94
46. Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administation of ischemia in rats. Stroke 2001;32(4):1005-1011
47. Ye M, Wang XJ, Zhang YH, Lu GQ, Liang L, Xu JY, Chen SD. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Brain Res,2007,1142:206-216.
48. Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy, 2008,10:340-352.
49. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG.. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol, 2006,198:54-64.
50. Mahmood A, Lu D, Chopp M. Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. J Neurotrauma,2004,21:33-39.
51. Kitada M, Dezawa M. Neural repair. Nippon Rinsho,2008,66(5):921-925.